Document is current

Any future updates will be listed below

Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database

Crossref DOI link: https://doi.org/10.1186/s13195-025-01735-5

Published Online: 2025-04-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark